All articles tagged: SARS-associated coronavirus as the cause of diseases classified elsewhere (B97.21)

Just under one-quarter of adults with self-reported COVID-19 report they had not recovered by 90 days, according to a study published online June 17 in JAMA Network Open.Elizabeth C. Oelsner, M.D., from the Columbia University Irving Medical Center in New York City, and colleagues used data from 14 ongoing National Institutes of

For individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the risks for death and postacute sequelae of COVID-19 (PASC) reduce over three years but persist, especially among hospitalized individuals, according to a study published online May 30 in Nature Medicine.Miao Cai, Ph.D., from the Veterans Af

The risk for prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) varies across immunosuppressive conditions, according to a study published in the Jan. 24 issue of Science Translational Medicine.Yijia Li, M.D., from Harvard Medical School in Boston, and colleagues performed a detailed viro-immunologic analysis of a

Maternal COVID-19 vaccination is associated with reduced frequency of neonatal respiratory distress (RD), according to a study published online Jan. 24 in Nature Communications.Olivia M. Man, from the David Geffen School of Medicine at the University of California in Los Angeles, and colleagues examined the association between matern

In children and adolescents, BNT162b2 was effective for COVID-19-related outcomes during the delta and omicron periods, according to a study published online Jan. 9 in the Annals of Internal Medicine.Qiong Wu, Ph.D., from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues examined the effectiveness

In children and adolescents, BNT162b2 was effective for COVID-19-related outcomes during the delta and omicron periods, according to a study published online Jan. 9 in the Annals of Internal Medicine.Qiong Wu, Ph.D., from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues examined the effectiveness

Treatment with nirmatrelvir during acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is not associated with a reduced risk for subsequent development of long COVID, according to a study published online Jan. 4 in the Journal of Medical Virology.Matthew S. Durstenfeld, M.D., from the University of California in

Few children with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection develop post-COVID-19 condition (PCC), according to a study published online Dec. 28 in JAMA Network Open.Frederick Dun-Dery, Ph.D., M.Phil., from the University of Calgary in Alberta, Canada, and colleagues quantified the prevalence of PCC among

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rebound occurs at a similar rate for those receiving and not receiving oral antiviral treatment and for those receiving nirmatrelvir/ritonavir or placebo, according to research published in the Dec. 22 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality We

For patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs (DMARDs), receiving a fourth COVID-19 mRNA vaccine reduces the risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to a study published online Nov. 15 in The Lancet Rheumatology.Jennifer S. Hanberg

The prevalence of olfactory dysfunction (OD) and gustatory dysfunction (GD) declines in the three years after COVID-19 infection, according to a research letter published online Nov. 9 in JAMA Otolaryngology-Head & Neck Surgery.Paolo Boscolo-Rizzo, M.D., from the University of Trieste in Italy, and colleagues estimated the three-

Maintenance immunosuppressive drugs are associated with an increased risk for COVID-19 hospitalization in solid organ transplant recipients, according to a study published online Nov. 7 in JAMA Network Open.Epiphane Kolla, M.D., M.P.H., from the French National Agency for the Safety of Medicines and Health Products in Paris, and co